Latest Drug discovery biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

How to select the perfect partner, next CPhI 2015 by 3PBiopharmaceuticals, Charles River, Covance and Menarini Biotech

by 3P Biopharmaceuticals

9 years ago
round table, CPhI, Covance, Charles River, Menarini Biotech, ASEBIO, 3P Biopharmaceuticals

"The challenge of Partner selection: the best travel companion in biologics drug development adventure” will discover the keys to success in this major challenge

Ability Pharmaceuticals announces regulatory milestones for ABTL0812 in pediatric cancer neuroblastoma

by Ability Pharma

9 years ago
pediatric cancer, neuroblastoma, orphan-drug, ABTL0812, Food and Drug Administration

Ability Pharmaceuticals today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation (ODD) for ABTL0812, its PI3K/Akt/mTOR pathway inhibitor, for the ...

Sanofi and AB-Biotics create formula to ease colic in babies

by Biocat

9 years ago
AB-Kolicare®, Sanofi, AB-Biotics, Baby colic

The probiotic formula, developed by the Catalan biotechnology company, will be the first that pharmaceutical corporation Sanofi will market in Spain

Hallan propiedades farmacéuticas para tratar la leucemia linfática crónica en un compuesto presente en el brócoli

by CSIC - Centro Superior de Investigaciones Científicas

9 years ago
brócoli, chronic lymphocytic leukemia, leukemia, Indole-3-carbinol, p53

Los autores del trabajo también destacan que el indol-3-carbinol “mejora notablemente” el efecto de la fludarabina, uno de los compuestos más utilizados en el tratamiento de este tipo de leucemi...

UB researchers develop a new family of bioinspired antibiotic compounds

by Xarxa de Referència en Biotecnologia (XRB)

9 years ago
antibacterial compound, peptides, Gram-negative bacteria, Gram-positive bacteria, antibiotics

The study has proved that these compounds are highly active against clinically relevant Gram-negative and Gram-positive bacteria. In vitro and in vivo tests have showed compounds’ low toxicity. Bact...

Ability Pharmaceuticals announces positive Phase 1/1b study results of ABTL0812 in cancer patients with advanced solid tumors

by Ability Pharma

9 years ago
cancer, ABTL0812, drug development, advanced solid tumors

Study confirms that ABTL0812 is extremely well tolerated and shows promising signs of clinical antitumor activity. The results will be presented at AACR-NCI-EORTC International Conference on Molecular...

Científicos de la Universidad de Granada patentan un nuevo fármaco eficaz frente al cáncer de mama, colon y melanoma

by Universidad de Granada

9 years ago
cáncer de mama, cáncer de colon, melanoma, fármaco, Células Madre Cancerígenas

El nuevo compuesto permitió reducir en más de un 50 por ciento la actividad tumoral tras 41 días de tratamiento, en ratones a los que previamente se les había inducido un tumor. Entre sus ventajas...

Palobiofarma signs licensing agreement to develop novel adenosine-based immuno-oncology treatments

by Palobiofarma

9 years ago
lung cancer, licensing agreement, drug development, PBF-509, Palobiofarma, Novartis

Under the terms of the agreement Novartis will acquire exclusive global rights to develop, manufacture and commercialize Palobiofarma´s adenosine A2Areceptor antagonist PBF-509, currently entering Ph...

New Trojan horses to conquer the brain

by IRB Barcelona - Instituto de Investigación Biomédica

9 years ago
neurologic diseases, brain, drug discovery, shuttle

20 pioneering scientists present their latest research on the barrier and the breakthroughs in therapeutic shuttle transporters that target the brain in the Blood-Brain-Barrier Conference, an event or...

Histocell obtains US patent for cell therapy product HC016

by Histocell Regenerative Medicine

9 years ago
patent, cell therapy, HC016, USPTO

Histocell, biopharmaceutical company focused on cell therapy and medical devices in the field of regenerative medicine, has obtained the patent in the United States for HC016 product.

Nuevas vías en el diseño de estrategias farmacológicas para el tratamiento de la hipertensión

by DiCYT - Agencia Iberoamericana para la Difusión de la Ciencia y la Tecnología

9 years ago
hipertensión, proteína kinasa 1, enfermedades cardiovasculares, ALK-1, neuronas, farmacología

La falta de la proteína ALK-1 induce hipertensión en ratones, según publica la revista científica 'Diseases Models and Mechanisms'

Immuron Commences NASH Companion Diagnostic Collaboration with OWL Metabolomics

by CRB Inverbío SA SGECR

9 years ago
Metabolomics), metabolomics, liver diseases, NASH, biomarker, OWL Metabolomics, Immuron Limited

Samples collected from the 120 patients to be enrolled during the Immuron NASH Phase II trial will be tested to assess the performance of the OWLiver test and some would be subjected to full metabolom...